Latest Strategic Business Development News

Butn Limited has reported its fifth consecutive half-year of revenue growth, underpinned by a $100 million senior debt facility and expanding platform originations. Despite a statutory loss, the company’s operational momentum and strategic initiatives signal robust growth prospects.

Stelar Metals is actively negotiating new project acquisitions across critical minerals while implementing cost-cutting measures to safeguard its cash position of $2.3 million at the end of September 2025.

Skylark Minerals has completed initial fieldwork at its Simon Copper Project in Mt Isa and launched a new rare-earths desktop study in Brazil, while actively pursuing new gold assets and re-engaging on its Greenland zinc project.

Podium Minerals has announced a major metallurgical breakthrough with a new concentrator flowsheet achieving approximately 80% recovery of key platinum group metals, advancing its Parks Reef Project towards commercialisation.

Objective Corporation Limited reported a solid 5% revenue increase to $123.5 million and a 13% rise in net profit after tax to $35.44 million for FY2025, alongside a strategic acquisition that broadens its e-planning software portfolio.

Etherstack plc has reported a remarkable turnaround in its half-year results, with revenue nearly doubling and EBITDA surging by over 1500%, signaling strong momentum in mission critical communications.

Skylark Minerals reports solid progress in its Simon Copper and Perseverance Projects with ongoing fieldwork analysis, while maintaining a strong cash position and advancing gold asset acquisitions.

Stonehorse Energy’s Q1 2025 report reveals Canadian wells outperforming production forecasts while revenue dips due to softer commodity prices. US operations show recovery, and the company intensifies Canadian business development amid market volatility.

LGI Limited reported a 7% rise in revenue and a 3% increase in EBITDA for H1 FY25, driven by expanded power generation capacity and higher landfill gas flows. However, net profit after tax declined by 22%, reflecting ongoing investment and market dynamics.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.

RareX Limited's December 2024 Quarterly Report reveals significant progress in its Khaleesi Niobium and Mt Mansbridge Heavy Rare Earth projects, setting the stage for targeted drilling campaigns in 2025. The company also highlights strategic business development and sustainability initiatives.

Hexima Limited has called off its planned acquisition of AI developer Real Thing Entertainment, ending the quarter with $1.64 million in cash and a cautious outlook on future strategic moves.